Gifu University Hospital and our company have started joint research on N-NOSE. This study examines the usefulness of “N-NOSE” cancer risk assessment in the treatment of solid tumors (esophagus, stomach, large intestine, pancreas, milk). Both sides will work on this research with the expectation that “N-NOSE” will go beyond the framework of screening tests and be established as an important test method in clinical practice.
TOKYO, JAPAN – March 6, 2026 – HIROTSU Bio Science Inc. announced the establishment of a new U.S. subsidiary, Hirotsu Global Inc., effectively c . . .
2026.03.06FOR IMMEDIATE RELEASE HIROTSU Bio Science Announces Referral of Former Employee to Prosecutors for Violation of the Unfair Competition Preven . . .
2026.02.05A novel, non-invasive approach to detecting micro-distant metastasis in highly lethal pancreatic cancer. TOKYO, JAPAN – January 5, 2026 – HIR . . .
2026.01.05